Sage Therapeutics, Inc.
SAGEDelisted Jul 31, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001597553
Sage Therapeutics, Inc. was delisted on Jul 31, 2025; its insiders filed their last Form 4 on Jul 31, 2025; 192 institutions reported holding it in 13F filings for Q2 2025, worth $445.6M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:39 PM ET
Revenue flow, FY2024
Where the revenue went in FY2024, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2024: $400.7M (971.5% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 11, 2025 | Feb 14, 2024 | Feb 16, 2023 | Feb 24, 2022 | Jan 7, 2021 |
| Revenue | $41.2M | $86.5M | $7.69M | $6.31M | $1.11B |
| Operating expenses | $473.6M | $666.3M | $554.7M | $467.2M | $518.0M |
| Research and development | $225.9M | $356.2M | $326.2M | $283.2M | $292.7M |
| Selling, general and administrative | $216.4M | $274.5M | $227.7M | $183.5M | $197.0M |
| Operating income | -$432.4M | -$579.8M | -$547.0M | -$460.9M | $596.2M |
| Net income | -$400.7M | -$541.5M | -$532.8M | -$457.9M | $606.1M |
| EPS, basic | $-6.59 | $-9.05 | $-8.98 | $-7.80 | $11.66 |
| EPS, diluted | $-6.59 | $-9.05 | $-8.98 | $-7.80 | $11.43 |
| Weighted shares, basic | 60.8M | 59.8M | 59.3M | 58.7M | 52.0M |
| Weighted shares, diluted | 60.8M | 59.8M | 59.3M | 58.7M | 53.0M |
| Margins and growth | |||||
| Operating margin | -1048.3% | -670.7% | -7116.7% | -7306.7% | 53.5% |
| Net margin | -971.5% | -626.3% | -6931.9% | -7258.9% | 54.4% |
| Revenue growth, year over year | −52.3% | +1,024.8% | +21.8% | −99.4% | +16,123.1% |
| Net income growth, year over year | – | – | – | −175.6% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 11, 2025 | Feb 14, 2024 | Feb 16, 2023 | Feb 24, 2022 | Jan 7, 2021 |
| Cash and equivalents | $81.0M | $71.0M | $162.7M | $294.2M | $1.66B |
| Short-term investments | $423.4M | $682.2M | $1.11B | $1.45B | $438.5M |
| Accounts receivable | $9.13M | $83.0M | – | – | – |
| Total current assets | $531.3M | $869.4M | $1.34B | $1.80B | $2.12B |
| Property, plant and equipment | $890.0K | $1.92M | $2.90M | $3.02M | $6.75M |
| Total assets | $547.2M | $882.3M | $1.36B | $1.83B | $2.16B |
| Accounts payable | $12.7M | $10.3M | $18.9M | $10.4M | $3.69M |
| Total current liabilities | $71.6M | $82.7M | $99.3M | $85.2M | $67.2M |
| Total liabilities | $82.1M | $82.7M | $103.8M | $96.3M | $86.9M |
| Shareholders' equity | $465.1M | $799.5M | $1.25B | $1.73B | $2.07B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 11, 2025 | Feb 14, 2024 | Feb 16, 2023 | Feb 24, 2022 | Jan 7, 2021 |
| Operating cash flow | -$267.2M | -$540.6M | -$460.0M | -$378.2M | $664.3M |
| Capital expenditures | $0 | $553.0K | $937.0K | $372.0K | $345.0K |
| Free cash flow | -$267.2M | -$541.1M | -$461.0M | -$378.6M | $663.9M |
| Stock-based compensation | $54.5M | $73.4M | $61.6M | $104.6M | $96.0M |
| Investing cash flow | $266.7M | $442.9M | $325.4M | -$1.00B | $442.7M |
| Financing cash flow | $10.7M | $6.03M | $3.07M | $13.3M | $426.8M |
| Net change in cash | $10.1M | -$91.6M | -$131.5M | -$1.37B | $1.53B |
| Ratio | |||||
| Stock-based compensation, % of revenue | 132.2% | 84.9% | 801.5% | 1658.7% | 8.6% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Jul 23, 2025 | 62.8M | +2.8% | SEC |
| Apr 22, 2025 | 62.6M | +4.1% | SEC |
| Feb 4, 2025 | 61.5M | +2.3% | SEC |
| Oct 22, 2024 | 61.2M | +2.0% | SEC |
| Jul 24, 2024 | 61.1M | +1.9% | SEC |
| Apr 18, 2024 | 60.2M | +0.7% | SEC |
| Feb 7, 2024 | 60.1M | +0.7% | SEC |
| Oct 31, 2023 | 60.0M | +0.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.